Type 2 diabetes (T2D) has become a burden for society, and the incidence of the disease continues to increase. A range of therapies is available to control glycaemia in T2D patients; however, these drugs have undesired side-effects and there is a need to develop improved treatments. Extensive research in diabetes has led to a better understanding of the disease and therefore to the design of new therapies. Incretin-based therapies are of special interest because they have numerous advantages over traditional treatments, for example, they do not produce hypoglycaemia and they induce weight loss, reduce appetite, provide β-cell protection, and reduce the risk of cardiovascular disease. There are two different incretin therapy approaches: glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors. In this article, the incretin-based therapies available on the market are described and compared with the traditional therapies to control diabetes. Finally, preventive steps are pointed out as an option to control diabetes, which has become a pandemic of the twenty-first century.
Editor-in-Chief
Co-Editors
Managing Editor
Victoria White
Associate Editors
Section Editors
Biotechnology
Digital Communication
EMWA News
Gained in Translation
Getting Your Foot in the Door
Good Writing Practice
In the Bookstores
Manuscript Writing
Medical Communications/Writing for Patients
Medical Devices
My First Medical Writing
News from the EMA
Out on Our Own
Pharmacovigilance
Regulatory Matters
Regulatory Public Disclosure
Teaching Medical Writing
The Crofter: Sustainable Communications
Veterinary Writing
Editors Emeritus
Lay out Designer
Chris Monk